Mauna Kea Technologies has earned CE mark approval in Europe to market Cellvizio UroFlex, which the company says is the first optical biopsy probe intended for urology uses. The device employs the firm's Cellvizio microscopy system, the use of which thus far has been limited to lung and gastrointestinal biopsies, to aid clinicians in diagnosing and monitoring bladder cancer.